Business
Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)
– TEV ‘325, which targets IL-13 and TSLP, is being studied for the treatment of TH2-driven inflammatory diseases such as asthma and atopic dermatitis – TEV ‘325 was computationally designed using Biolojic’s Multibody Platform – WASHINGTON and NESS ZIONA, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology company that uses AI to transform antibodies into multifunctional, programmable medicines, today announced it has earned an additional milestone payment from its collabo
About this update from Teva Pharmaceutical Industries Limited
[{"type":"image","alt":"Biolojic Design","displaySize":"","headline":null,"caption":"Biolojic Design","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/4f3c9721e81d8a382eda08ba467d0618"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/q49ENr1cws7qr2RydeWDzQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/4f3c9721e81d8a382eda08ba467d0618","width":300,"height":300}},"lazy":false},{"type":"text","content":"– TEV ‘325, which targets IL-13 and TSLP, is being studied for the treatment of TH2-driven inflammatory diseases such as asthma and atopic dermatitis","length":149,"tagName":"p"},{"type":"text","content":"– TEV ‘325 was computationally designed using Biolojic’s Multibody Platform –","length":77,"tagName":"p"},{"type":"text","content":"WASHINGTON and NESS ZIONA, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology company that uses AI to transform antibodies into multifunctional, programmable medicines, today announced it has earned an additional milestone payment from its collaboration partner, Teva Pharmaceutical Industries Ltd. (Teva), as TEV ‘325 (formerly BD9), a multibody targeting IL-13 and thymic stromal lymphopoietin (TSLP), has achieved a preclinical milestone. Teva has an exclusive license to develop and commercialize TEV ‘325 for the treatment of TH2-driven inflammatory diseases such as asthma and atopic dermatitis.","length":626,"tagName":"p"},{"type":"text","content":"“We’re excited that TEV ‘325 continues to advance through preclinical development and look forward to Teva’s initiation of clinical trials targeted for 2027,” said Yanay Ofran, PhD, CEO and founder of Biolojic Design. “TEV ‘325 is our first multibody in development for autoimmune disease and, if it progresses, could become the second multibody and third AI-designed molecule from our platform to enter clinical trials. This reflects Biolojic’s leadership position at the forefront of the AI-design revolution. These assets illustrate how AI can solve clinical problems that other technologies have been struggling with for years.”","length":632,"tagName":"p"},{"type":"text","content":"TEV ‘325 is a multibody, a new type of antibody designed to execute multiple, complex functions while maintaining all the advantages of the simple, d...